Reduced EtO emissions to safeguard biomedical supply chains
Reduced EtO emissions to safeguard biomedical supply chains
批准号:
10547016
负责人:
Melissa A Petruska
金额:
$20.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-20 至 2023-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Summary/Abstract
The overarching goal of this project is to protect the nation’s supply chain of critical medical
devices that are sterilized using ethylene oxide (EtO). Despite the search for alternative
approaches, numerous types of single-use devices are sterilized with EtO. These devices,
including catheters, heart valves, and tracheostomy tubes, are critical to routine and life-saving
procedures and therapies. As regulation of EtO emissions and community and worker exposure
levels continues to become more stringent, there is a threat that supply chains for critical devices
will be disrupted, in turn threatening the health and well-being of the nation. The specific
objectives of this project include the development of a novel photocatalytic method to mitigate
EtO at levels that are hazardous but difficult to address with existing adsorptive and thermal
catalytic approaches. Specifically, the technology addresses concentrations in the range of 10 ppm
and below. The technology can be used to mitigate EtO from existing sterilization plants as an
adjunct to stack scrubbers, as well as deployed to address ambient levels of EtO in plants and
warehouses. Objectives include determining operating conditions at which low concentrations of
EtO (<10 ppm) are oxidized at 99% destruction and removal efficiency (DRE), identifying
optimum photocatalyst and parameter space for achieving high DRE, developing a prototype
photoreactor operating at 20 cfm capable of 99% EtO DRE that is scalable to commercial
requirements, and evaluating the performance of the prototype for a target 99% EtO DRE at 20
cfm. The specific aims are determining operating parameters at lab-scale, building a scalable
prototype reactor capable of 20 cfm operation, and evaluating the performance of the prototype
at 20 cfm for a target of 99% EtO DRE. Study designs are centered around systematic catalyst
modifications and exploration of gas flow / illumination geometries. Standard and cutting-edge
detection approaches that are capable of measuring EtO into the low ppb and ppt ranges will be
used in the experimental program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reduced EtO emissions to safeguard biomedical supply chains
-
批准号:10827793
-
项目类别:
-
资助金额:$59.1万
-
财政年份:2022
-
负责人:Melissa A Petruska
-
依托单位:
国内基金
海外基金
登录
查看更多内容
组蛋白甲基化酶SETD2和RNA甲基化酶METTL3串扰调控选择性剪接体AML1-ETO9a的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:李永辉
-
依托单位:
BAHD1在AML1-ETO阳性儿童急性髓系白血病中的表达、促进白血病发生和复发分子机制研究
-
批准号:82370156
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:范会涛
-
依托单位:
AML1-ETO/SETD8新型复合体增强染色质可及性维持t(8;21)AML白血病干细胞干性的新机制
-
批准号:82304555
-
项目类别:青年科学基金项目
-
资助金额:20万元
-
批准年份:2023
-
负责人:苏永伟
-
依托单位:
双靶向AML1-ETO融合癌蛋白与c-Kit突变体治疗t(8;21)急性髓系白血病的分子机制研究
-
批准号:82370151
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:俞文娟
-
依托单位:
METTL3/FTO-IGF2BP2-SRSF2/6轴在急性髓系白血病选择性剪接体AML1-ETO9a产生中的表观遗传学调控机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:李永辉
-
依托单位:
AML1-ETO/CDK12复合物促进超级增强子活性维持t(8;21)急性髓系白血病干细胞干性的机制研究
-
批准号:82270172
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:周景峰
-
依托单位:
AML1-ETO融合蛋白调控NR4A2的表观遗传学沉默促进t(8;21)急性髓系白血病发生发展的分子机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:黄赛
-
依托单位:
MDSC在AML1-ETO+AML恶性维持和化疗抵抗中的功能和机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:余山河
-
依托单位:
AML1-ETO相关融合环状RNA通过ENO1调控白血病细胞糖酵解的作用研究
-
批准号:82100196
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:王颖
-
依托单位:
AML-ETO9a的产生及驱动t(8;21)AML细胞发生恶性转化的机制研究
-
批准号:--
-
项目类别:重点项目
-
资助金额:297万元
-
批准年份:2020
-
负责人:于力
-
依托单位: